Patent ID: 6727245
Filing Date: 2004-04-27
Classification: A61P,C07D

Abstract:
A method for treating a disease or disorder mediated by phosphodiesterase IV (PDE-IV), tumor necrosis factor (TNF), or both, comprising administering an effective amount of a compound of formula (I) to a subject in need thereof, wherein the compound of formula (I) is: wherein R1 is aryl which may have one or more suitable substituent(s), ar(lower)alkyl which may have one or more suitable substituent(s), halo(lower)alkyl, carboxyethyl, protected carboxy(lower)alkyl, acyl(lower)alkyl, a heterocyclic group which may have one or more suitable substituent(s) or a heterocyclic(lower)alkyl group which may have one or more suitable substituent(s); R2 is aryl which may have one or more suitable substituent(s) or a heterocyclic group, and R3 is hydrogen, lower alkoxy or arylthio, or a pharmaceutically acceptable salt thereof; provided that when R1 is phenyl, halophenyl, trihalo(lower)alkyl, carboxyethyl, piperidyl, morpholinyl, piperazinyl, or alkylpiperazinyl, then R2 is not substituted phenyl, piperidyl, morpholinyl, piperazinyl, or alkylpiperazinyl, and wherein the disease or disorder is selected from the group consisting of, osteoporosis, transplantation rejection, asthma, eosinophilia, cystic fibrosis, hepatitis, pancreatitis, nephritis, endotoxic shock, ankylosing spondylitis, an autoimmune hematological disorder, polychondritis, scleroderma, Wegener granulamotosis, dermatomyositis, chronic active hepatitis, atopic dermatitis, psoriasis, idiopathic sprue, autoimmune inflammatory bowel disease, endocrine ophthalmopathy, Grave's disease, sarcoidosis, multiple sclerosis, primary biliary cirrhosis, juvenile diabetes (diabetes mellitus type I), Reiter's syndrome, non infection uveitis, autoimmune keratitis, interstitial lung fibrosis, psoriatic arthritis, cancer cachexia, AIDS cachexia, and thrombosis.